CN104010634B - 用于治疗神经系统病症的组合物 - Google Patents

用于治疗神经系统病症的组合物 Download PDF

Info

Publication number
CN104010634B
CN104010634B CN201280026514.3A CN201280026514A CN104010634B CN 104010634 B CN104010634 B CN 104010634B CN 201280026514 A CN201280026514 A CN 201280026514A CN 104010634 B CN104010634 B CN 104010634B
Authority
CN
China
Prior art keywords
acid
group
patients
agent
study
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN201280026514.3A
Other languages
English (en)
Chinese (zh)
Other versions
CN104010634A (zh
Inventor
马里奥斯·潘特艾瑞斯
杨尼斯·帕特瑞克奥斯
乔治斯·路凯迪斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pa Lupa Medicine Co Ltd
Original Assignee
Pa Lupa Medicine Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46275907&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CN104010634(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pa Lupa Medicine Co Ltd filed Critical Pa Lupa Medicine Co Ltd
Publication of CN104010634A publication Critical patent/CN104010634A/zh
Application granted granted Critical
Publication of CN104010634B publication Critical patent/CN104010634B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/01—Hydrocarbons
    • A61K31/015—Hydrocarbons carbocyclic
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A61K31/355—Tocopherols, e.g. vitamin E
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Polymers & Plastics (AREA)
  • Dispersion Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
CN201280026514.3A 2011-03-29 2012-03-28 用于治疗神经系统病症的组合物 Expired - Fee Related CN104010634B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161469081P 2011-03-29 2011-03-29
US61/469,081 2011-03-29
PCT/IB2012/000824 WO2012131493A1 (en) 2011-03-29 2012-03-28 Compositions for the treatment of neurologic disorders

Publications (2)

Publication Number Publication Date
CN104010634A CN104010634A (zh) 2014-08-27
CN104010634B true CN104010634B (zh) 2017-06-09

Family

ID=46275907

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280026514.3A Expired - Fee Related CN104010634B (zh) 2011-03-29 2012-03-28 用于治疗神经系统病症的组合物

Country Status (20)

Country Link
US (2) US20120252888A1 (cg-RX-API-DMAC7.html)
EP (1) EP2691086B1 (cg-RX-API-DMAC7.html)
JP (1) JP6092843B2 (cg-RX-API-DMAC7.html)
CN (1) CN104010634B (cg-RX-API-DMAC7.html)
AU (1) AU2012235869B2 (cg-RX-API-DMAC7.html)
BR (1) BR112013025088B1 (cg-RX-API-DMAC7.html)
CA (1) CA2831506C (cg-RX-API-DMAC7.html)
CY (1) CY1117828T1 (cg-RX-API-DMAC7.html)
DK (1) DK2691086T3 (cg-RX-API-DMAC7.html)
EA (1) EA025232B1 (cg-RX-API-DMAC7.html)
ES (1) ES2585066T3 (cg-RX-API-DMAC7.html)
GE (1) GEP201606568B (cg-RX-API-DMAC7.html)
HR (1) HRP20160939T1 (cg-RX-API-DMAC7.html)
HU (1) HUE028065T2 (cg-RX-API-DMAC7.html)
IL (1) IL228541A (cg-RX-API-DMAC7.html)
MX (1) MX2013011295A (cg-RX-API-DMAC7.html)
PL (1) PL2691086T3 (cg-RX-API-DMAC7.html)
UA (1) UA114706C2 (cg-RX-API-DMAC7.html)
WO (1) WO2012131493A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201307256B (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10709680B2 (en) * 2011-07-18 2020-07-14 Physicians Recommended Nutriceuticals, Llc Methods for treating dry eye
ITMI20130354A1 (it) * 2013-03-08 2014-09-09 Again Life Italia Srl Miscela di acidi grassi (f.a.g. fatty acids group) per uso nel trattamento di patologie infiammatorie.
CN105828816A (zh) * 2013-11-12 2016-08-03 雅培公司 包含天然维生素e和多不饱和脂肪酸的营养组合物的用途
KR102400958B1 (ko) 2014-06-06 2022-05-20 마린 인그리디언츠, 엘엘씨 오메가-3 조성물, 제형 및 사용 방법
JP2018518451A (ja) * 2014-11-07 2018-07-12 マゼ ジョリー ヴァダケムリ 最適化された栄養分の脂肪酸組成
DE102015109352A1 (de) * 2015-06-12 2016-12-15 K. D. Pharma Bexbach Gmbh Anwendung von Omega-3- und/oder Omega-6-Fettsäure(n)
AR102008A1 (es) * 2015-09-24 2017-01-25 Brix S R L Ingrediente farmacéutico activo (ifa) oleoso para el tratamiento de afecciones de la piel, composiciones que lo comprenden y su uso para prepararlas
WO2017213490A1 (en) 2016-06-10 2017-12-14 N.V. Nutricia Method for controlling neuroinflammation
BR112019008739A2 (pt) 2016-11-04 2019-07-09 Immd Sp Zo O distribuição inteligente de moléculas ingeridas e absorvidas
CN109125311A (zh) * 2018-06-26 2019-01-04 东南大学 预防或治疗阿尔茨海默症的药物组合物及其应用
WO2022170226A1 (en) * 2021-02-08 2022-08-11 Synaptogenix, Inc. Treatment of optic nerve inflammation using pkc activators
US20240180869A1 (en) * 2021-02-08 2024-06-06 Synaptogenix, Inc. Treatment of multiple sclerosis using pkc activators
US12048681B2 (en) * 2021-08-09 2024-07-30 Kentucky Equine Research, Inc. Compositions and methods for modulating equine fatty acid profiles

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0440341A1 (en) * 1990-01-18 1991-08-07 Scotia Holdings Plc EFA compositions and therapy
CN1282223A (zh) * 1997-12-23 2001-01-31 利尔生公司 脂肪掺合物

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8601399D0 (en) * 1986-01-21 1986-02-26 Delta Iota Ltd Information transmission/processing
GB8601915D0 (en) * 1986-01-27 1986-03-05 Efamol Ltd Pharmaceutical compositions
GB8813766D0 (en) 1988-06-10 1988-07-13 Efamol Holdings Essential fatty acid compositions
PH31403A (en) * 1991-03-01 1998-10-29 Warner Lambert Co Therapeutic compositions to protect and recuscitate mammalian cells and methods for preparing same.
GB9111900D0 (en) * 1991-06-03 1991-07-24 Efamol Holdings Fatty acid compositions
JP3283274B2 (ja) * 1991-06-15 2002-05-20 サントリー株式会社 新規組成物
GB9506837D0 (en) * 1995-04-03 1995-05-24 Scotia Holdings Plc Triglycerides
US6048891A (en) * 1998-12-17 2000-04-11 Loma Linda University Medical Center Use of γ-tocopherol and its oxidative metabolite LLU-α in the treatment of natriuretic disease
GB9901809D0 (en) * 1999-01-27 1999-03-17 Scarista Limited Highly purified ethgyl epa and other epa derivatives for psychiatric and neurological disorderes
US6677321B1 (en) * 1999-12-09 2004-01-13 Bruce Levin Methods and compositions for treatment of inflammatory disease
US7045683B2 (en) 2001-05-04 2006-05-16 Abbott Laboratories Δ4-desaturase genes and uses thereof
DE60203494T2 (de) * 2001-05-30 2006-02-09 Laxdale Ltd. Verwendung von coenzym q (ubiquinone) und eikosapentaensäure (epa) für die behandlung von non-hodgkin's lymphoma und psychiatrischen oder neurologischen erkrankungen
PT1417211E (pt) 2001-07-27 2007-08-28 Neptune Technologies & Bioress Fosfolípidos naturais de origem marinha contendo flavonóides e fosfolípidos polinsaturados e suas utilizações.
US20030144219A1 (en) * 2001-11-15 2003-07-31 Phinney Stephen Dodge Formulations and methods for treatment or amelioration of inflammatory conditions
US20050080109A1 (en) 2003-10-09 2005-04-14 Papas Andreas M. Gamma-tocopherol and gamma-tocotrienol therapy for multiple sclerosis
NZ569676A (en) * 2005-12-21 2012-03-30 Brudy Technology S L Use of DHA, EPA or DHA-derived EPA for treating a pathology associated with cellular oxidative damage
US20090196862A1 (en) * 2008-01-22 2009-08-06 William Davis High dosage Vitamin D
JP2010155799A (ja) * 2008-12-26 2010-07-15 Fujifilm Corp 粉末組成物及びそれを含む食品
WO2010118761A1 (en) * 2009-04-17 2010-10-21 Eolas Science Limited Compositions rich in omega-3 fatty acids with a low content in phytanic acid

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0440341A1 (en) * 1990-01-18 1991-08-07 Scotia Holdings Plc EFA compositions and therapy
CN1282223A (zh) * 1997-12-23 2001-01-31 利尔生公司 脂肪掺合物

Also Published As

Publication number Publication date
BR112013025088A2 (pt) 2017-02-14
MX2013011295A (es) 2014-11-10
EP2691086B1 (en) 2016-04-27
EA025232B1 (ru) 2016-12-30
DK2691086T3 (en) 2016-08-15
UA114706C2 (uk) 2017-07-25
GEP201606568B (en) 2016-11-10
US20190343774A1 (en) 2019-11-14
JP6092843B2 (ja) 2017-03-08
ZA201307256B (en) 2014-12-23
HRP20160939T1 (hr) 2016-10-07
PL2691086T3 (pl) 2016-12-30
HK1194665A1 (zh) 2014-10-24
CN104010634A (zh) 2014-08-27
AU2012235869B2 (en) 2017-04-20
JP2014512351A (ja) 2014-05-22
BR112013025088B1 (pt) 2021-12-14
HUE028065T2 (en) 2016-11-28
CA2831506A1 (en) 2012-10-04
WO2012131493A1 (en) 2012-10-04
NZ616554A (en) 2015-10-30
US20120252888A1 (en) 2012-10-04
ES2585066T3 (es) 2016-10-03
EP2691086A1 (en) 2014-02-05
AU2012235869A1 (en) 2013-10-17
CA2831506C (en) 2019-07-09
EA201391407A1 (ru) 2014-03-31
IL228541A0 (en) 2013-12-31
IL228541A (en) 2017-11-30
CY1117828T1 (el) 2017-05-17

Similar Documents

Publication Publication Date Title
CN104010634B (zh) 用于治疗神经系统病症的组合物
US10342773B2 (en) Composition containing dihomo-γ-linolenic acid (DGLA) as the active ingredient
US20100261791A1 (en) Compositions and Methods for Improving or Preserving Brain Function
JP4986321B2 (ja) 炎症性状態処置のための方法および組成物
CN101842103A (zh) 用于脑部健康的单位剂量
JP2007238441A (ja) アスタキサンチンを有効成分とする体脂肪減少用組成物
HK1039281A1 (en) Pharmaceutical composition for treatment of inflammatory conditions and the relevant use
KR100858988B1 (ko) 치료제
US20230346699A1 (en) Administration of r-beta-hydroxybutyrate and related compounds in veterinary applications
US20140343143A1 (en) Use of highly concentrated compositions of selected n-3 fatty acids for the treatment of central nervous system disturbances
NZ616554B2 (en) Compositions for the treatment of neurologic disorders
HK1194665B (en) Compositions for the treatment of neurologic disorders
JP2009019025A (ja) 非ヒト動物の老化又は痴呆に伴う疾患又は症状の改善剤
JP2020145941A (ja) アレルギー性鼻炎抑制用組成物
WO2007084648A2 (en) Mixed 4→6 procyanidin dimers and their use

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20170609